Revenues Up Despite Paroxetine Competition And Disappointing Ribavirin Launch, Par Says
This article was originally published in The Pink Sheet Daily
Par's second quarter revenues jumped despite disappointing revenues from the company's ribavirin generic and lower sales for paroxetine
You may also be interested in...
Andrx will market Alphapharm's generic paroxetine (GlaxoSmithKline's Paxil) "shortly" under an agreement announced May 12
Three Rivers/Par launch Ribasphere at a 10% discount to Schering-Plough’s Rebetol. The generics are approved for use in combination with interferon alfa-2b for the treatment of hepatitis C.
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability